Focused On-demand Library for Voltage-dependent L-type calcium channel subunit alpha-1F

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.

 Fig. 1. The sreening workflow of Receptor.AI

The method involves in-depth molecular simulations of the ion channel in its native membrane environment, including its open, closed, and inactivated states, along with ensemble virtual screening that focuses on conformational mobility for each state. Tentative binding pockets are identified inside the pore, in the gating area, and at allosteric sites to address every conceivable mechanism of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Voltage-gated calcium channel subunit alpha Cav1.4

Alternative UPACC:

O60840; A6NI29; F5CIQ9; O43901; O95226; Q9UHB1


The Voltage-dependent L-type calcium channel subunit alpha-1F, also known as Cav1.4, plays a crucial role in the entry of calcium ions into excitable cells. It is pivotal in various calcium-dependent processes such as muscle contraction, hormone release, and cell death. This protein generates L-type calcium currents, activating at more negative voltages without undergoing calcium-dependent inactivation.

Therapeutic significance:

Cav1.4 is implicated in several retinal disorders, including congenital stationary night blindness, cone-rod dystrophy, and Aaland island eye disease. These conditions highlight the protein's significance in visual function and underscore the potential of targeting Cav1.4 in therapeutic strategies aimed at mitigating visual impairment.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.